Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

WILMETTE, Ill., March 28, 2024 -- Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth...

Related Keywords

Australia ,Monopartx Linkedin ,Kimr Tsuchimoto ,Rodney Hicks ,Exchange Commission ,Radiopharmaceutical Program ,Nasdaq ,Monopar Therapeutics Inc ,Melbourne Theranostic Innovation Centre ,Human Research Ethics Committee ,Development Rd Expenses ,Twitter ,Professor Rodney Hicks ,Dose Escalation Trial ,Fifth Dose Level Cohort ,Fourth Quarter ,Year Ended December ,Private Securities Litigation Reform Act ,Professor Hicks ,Financial Officer ,